Cequent Files its First IND with FDA for a tkRNAi Drug Candidate, CEQ508
News Nov 16, 2009
Cequent Pharmaceuticals has announced that it has filed its first IND (investigational new drug) application with the U.S. Food and Drug Administration (FDA).
CEQ508, an orally administered tkRNAi drug candidate, targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer.
Cequent expects to begin the Phase I clinical trial in the FAP (familial adenomatous polyposis) patient population during the first quarter of 2010 at the Fred Hutchinson Cancer Research Center, in Seattle, Washington, part of the Fred Hutchinson/University of Washington Cancer Consortium.
“A first IND filing is obviously a momentous event for a young company like Cequent, and this is also a critical milestone in the development of RNAi therapeutics in general, as our proposed Phase I trial will be the first test of an orally administered RNA interference drug in humans,” said Cequent Chief Executive Officer Peter Parker.
“In 2006, when RNAi was the subject of the Nobel Prize in Medicine, it was hailed as ‘a revolution in biology’ – RNAi’s discovery created the opportunity to address targets that were previously difficult to treat by effectively deactivating the specific gene or genes implicated in the progression of a disease by “interfering” with messenger RNA. However, success in developing RNAi therapies has been elusive to date because of delivery issues – how do you transport and deposit the molecules triggering RNAi into the target cells and diseased tissues. We believe that our orally administered tkRNAi technology has shown great potential in solving that significant problem.”
This Phase I clinical trial, as proposed to the FDA, would be conducted to determine safety and tolerability of CEQ508 at escalating doses in a total of 18 adult FAP patients. A key readout and secondary objective of the proposed trial includes analysis of biomarker (beta-catenin) expression changes in the gastrointestinal tract of patients determined from biopsy samples taken prior to taking the drug, and following a daily, 28-day dosing regimen.
The principal investigator (PI) of this clinical trial will be Gideon Steinbach, M.D., Ph.D., associate professor of medicine at the University of Washington and the PI of a number of earlier FAP studies.
The Cancer Consortium maintains a registry of FAP patients and is also one of 40 National Cancer Institute-designated comprehensive cancer centers nationwide.
In preclinical testing with non-human primates, tkRNAi therapeutic candidates have demonstrated potent silencing of the beta-catenin, a protein known to accumulate and lead to the proliferation of polyps in affected patients. During preclinical testing, CEQ508 demonstrated an encouraging safety profile when administered as a daily oral therapeutic.
About 422 million people around the world, including more than 30 million Americans, have diabetes. Obesity is the most significant risk factor for type 2 diabetes. yet about 30 percent of obese people do not develop type 2 diabetes or other metabolic conditions. New research aims to understand on a cellular level, how this separation occurs.READ MORE
Habitat loss, habitat fragmentation and the loss of genetic diversity are the main factors driving the extinction of many wild species, and the few eastern massasauga rattlesnakes remaining in Illinois have certainly suffered two of the three. A long-term study of these snakes reveals, however, that – despite their alarming decline in numbers – they have retained a surprising amount of genetic diversity.READ MORE